Table 1

Changes in metastasis of KoTCC-1 cells injected into the bladder wall of nude mice after antisense clusterin ODN and/or cisplatin treatment

RegimenbIncidence of metastasis (%)aWeight of the primary tumor (mg)
Retroperitoneal lymph node metastasisIntraabdominal lymph node metastasisIncidence of hemorrhagic ascitesc
AS clusterin ODN10/10 (100)7/10 (70)6/10 (60)39.2 ± 9.5d
MM control ODN10/10 (100)9/10 (90)7/10 (70)41.1 ± 10.1
AS clusterin ODN + cisplatin1/10 (10)e0/10 (0)e0/10 (0)e20.6 ± 7.1f
MM control ODN + cisplatin6/10 (60)5/10 (50)4/10 (40)33.6 ± 9.2
  • a Number of mice with tumor/number of injected mice.

  • b Two weeks after the implantation of tumor cells, 10 mg/kg AS clusterin ODN or MM clusterin ODN was injected i.p., and 50 μg of cisplatin was injected i.v. twice a week for 2 weeks.

  • c Number of mice with hemorrhagic ascites/number of injected mice.

  • d Mean ±SD.

  • e The incidence of metastasis or hemorrhagic ascites was significantly different from that in mice treated with other regimens (P < 0.05, χd test).

  • f The mean weight of the primarytumor was significantly different from that in mice treated with other regimens (P < 0.005, Student’s t test).